Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF

In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure), dapagliflozin, added to guideline-recommended therapies, reduced the risk of mortality and heart failure (HF) hospitalization. We examined the frequency and significance of episodes of outpatient HF worsening,...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Circulation
المؤلفون الرئيسيون: Docherty, Kieran F., Jhund, Pardeep S., Anand, Inder, Bengtsson, Olof, Böhm, Michael, de Boer, Rudolf A., DeMets, David L., Desai, Akshay S., Drozdz, Jaroslaw, Howlett, Jonathan, Inzucchi, Silvio E., Johanson, Per, Katova, Tzvetana, Køber, Lars, Kosiborod, Mikhail N., Langkilde, Anna Maria, Lindholm, Daniel, Martinez, Felipe A., Merkely, Béla, Nicolau, Jose C., O’Meara, Eileen, Ponikowski, Piotr, Sabatine, Marc S., Sjöstrand, Mikaela, Solomon, Scott D., Tereshchenko, Sergey, Verma, Subodh, McMurray, John J.V.
التنسيق: Artigo
اللغة:Inglês
منشور في: Lippincott Williams & Wilkins 2020
الموضوعات:
Original Research Articles
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC7580857/
https://ncbi.nlm.nih.gov/pubmed/32883108
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.120.047480
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة